Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,478 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Carcinoma Clear all
Active, not recruiting Not applicable Interventional

Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules

NCT06638398
View directory record Official record
Conditions
Lung Neoplasm
Interventions
Computed Tomography, Diagnostic Procedure, Best Practice, Electronic Health Record Review
Procedure · Device · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
35 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • St Louis, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

NCT01594398
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer
Interventions
entinostat, Erlotinib, Exemestane
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors

NCT00528619
View directory record Official record
Conditions
Neoplasms
Interventions
Sunitinib, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 7, 2011 · Synced Sep 16, 2026, 10:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

NCT03556228
View directory record Official record
Conditions
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Mesothelioma, Esophageal Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, Salivary Gland Carcinomas, Head and Neck Cancers - Salivary Gland, Head and Neck Cancers - Nasopharyngeal, Head and Neck Cancers - Throat, Small Cell Lung Cancer ( SCLC ), Lung Cancer (Locally Advanced or Metastatic), Head and Neck Cancers - Tonsils, Head and Neck Cancers Hypopharynx, Head and Neck Cancers Larynx, Head and Neck Cancers Lip, Head and Neck Cancers Nasopharynx, Head and Neck Cancers Oral Cavity, Head and Neck Cancers, Head and Neck Cancers Oropharynx, Head and Neck Cancers Trachea
Interventions
VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
Drug
Lead sponsor
VM Oncology, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
14
States / cities
Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 16, 2026, 10:45 AM EDT
Active, not recruiting Phase 2 Interventional Results available

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

NCT04619004
View directory record Official record
Conditions
Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Interventions
Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
33
States / cities
Gilbert, Arizona • Duarte, California • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Terminated Phase 1 Interventional

Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

NCT01911325
View directory record Official record
Conditions
Squamous Non-small Cell Lung Cancer
Interventions
Buparlisib, Buparlisib matching placebo, Docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Fayetteville, Arkansas • Tampa, Florida • Worcester, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Sep 16, 2026, 10:45 AM EDT
Completed No phase listed Observational

Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer

NCT00897650
View directory record Official record
Conditions
Lung Cancer
Interventions
DNA/RNA sequencing and expression levels, Protein expression analysis, Lung tumor biopsy, Blood sample
Genetic · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 16, 2026, 10:45 AM EDT
Recruiting Phase 1 Interventional

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

NCT06171750
View directory record Official record
Conditions
Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor, Solid Tumor, Metastatic Solid Tumor, Metastasis to Soft Tissue, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma
Interventions
tolododekin alfa, Cemiplimab
Drug
Lead sponsor
Ankyra Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Bethesda, Maryland • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

NCT07491497
View directory record Official record
Conditions
ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer
Interventions
TRI-611
Drug
Lead sponsor
TRIANA Biomedicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage

NCT00887159
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma
Interventions
Cisplatin, Cixutumumab, Etoposide, Laboratory Biomarker Analysis, Vismodegib
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
301
States / cities
Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 205 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

NCT00712504
View directory record Official record
Conditions
Advanced Solid Tumors, Non Small Cell Lung Cancer
Interventions
sunitinib, docetaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
5
States / cities
Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 10, 2008 · Synced Sep 16, 2026, 10:45 AM EDT
Not yet recruiting Phase 2 Interventional

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

NCT05859217
View directory record Official record
Conditions
Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC
Interventions
Cabozantinib, Atezolizumab
Drug
Lead sponsor
Jun Zhang, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Kansas City, Kansas • Overland Park, Kansas • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 16, 2026, 10:45 AM EDT
Terminated Phase 1 Interventional

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

NCT03275597
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
Interventions
Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 16, 2026, 10:45 AM EDT
Withdrawn Phase 2 Interventional

A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer

NCT00697060
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Imexon + docetaxel
Drug
Lead sponsor
AmpliMed Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Sep 16, 2026, 10:45 AM EDT
Completed No phase listed Observational

Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy

NCT00442520
View directory record Official record
Conditions
Lung Cancer, Colorectal Cancer, Head and Neck Cancer
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Sep 16, 2026, 10:45 AM EDT
Recruiting No phase listed Observational

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

NCT06122077
View directory record Official record
Conditions
Lung Cancer Diagnosis
Interventions
blood draw
Diagnostic Test
Lead sponsor
Freenome Holdings Inc.
Industry
Eligibility
50 Years and older
Enrollment
20,000 participants
Timeline
2023 – 2027
U.S. locations
36
States / cities
Los Angeles, California • Stamford, Connecticut • DeLand, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

BATTLE Program: Sorafenib in Patients With NSCLC

NCT00411671
View directory record Official record
Conditions
Lung Cancer
Interventions
Sorafenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers

NCT02123849
View directory record Official record
Conditions
Lung Carcinoma, Tobacco Use Disorder
Interventions
Aspirin, Laboratory Biomarker Analysis, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
2
States / cities
Tucson, Arizona • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

NCT01204476
View directory record Official record
Conditions
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma
Interventions
Cixutumumab, Everolimus, Laboratory Biomarker Analysis, Octreotide Acetate, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Proactive Outreach and Shared Decision Making in Improving Lung Cancer Screening Rates in Primary Care Patients

NCT03929926
View directory record Official record
Conditions
Lung Cancer
Interventions
Best Practice, Cancer Educational Materials, Behavioral, Psychological or Informational Intervention, Counseling
Other · Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
55 Years to 80 Years
Enrollment
2,355 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Sep 16, 2026, 10:45 AM EDT
Terminated Phase 2 Interventional Results available

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

NCT01032850
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Sorafenib & Capecitabine
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 16, 2026, 10:45 AM EDT
Terminated Phase 3 Interventional Results available

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

NCT00300885
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel, Carboplatin plus Paclitaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
80
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 16, 2026, 10:45 AM EDT
Terminated Phase 2 Interventional Results available

Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava

NCT05081882
View directory record Official record
Conditions
Smoking
Interventions
Kava, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 99 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

NCT00022308
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, irinotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
8
States / cities
Millville, New Jersey • Mount Holly, New Jersey • Red Bank, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2013 · Synced Sep 16, 2026, 10:45 AM EDT